If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> HEPATOLOGY<br /> ISSN 2053-4221 Vol 4.1 • May 2016 • emjreviews.com<br /> INSIDE<br /> Review of<br /> ILC 2016<br /> Barcelona, Spain<br /> CONTENTS<br /> EDITORIAL BOARD......................................................................................................................................... 4<br /> CONGRESS REVIEW........................................................................................................................................ 10<br /> • Review of the International Liver Congress (ILC) 2016, held in Barcelona, Spain,<br /> 13th–17th April 2016<br /> INTERVIEWS WITH EMJ HEPATOLOGY EDITORIAL BOARD................................................................ 28<br /> SYMPOSIUM REVIEW<br /> • WELCOME TO THE REAL WORLD: HEPATITIS C VIRUS CLINICAL TRIALS TO<br /> PATIENT REALITIES..........................................................<a title="EMJ Hepatology 4.1 2016 page 1" href="http://viewer.zmags.com/publication/ac549839?page=1"> HEPATOLOGY ISSN 2053-4221 </a> <a title="EMJ Hepatology 4.1 2016 page 2" href="http://viewer.zmags.com/publication/ac549839?page=2"> CONTENTS EDITORIAL BOARD.......................</a> <a title="EMJ Hepatology 4.1 2016 page 3" href="http://viewer.zmags.com/publication/ac549839?page=3"> HEPATOLOGY • NONSURGICAL TREATMENT FOR LOCALI</a> <a title="EMJ Hepatology 4.1 2016 page 4" href="http://viewer.zmags.com/publication/ac549839?page=4"> Editorial Board Editor-in-Chief: Prof Markus P</a> <a title="EMJ Hepatology 4.1 2016 page 5" href="http://viewer.zmags.com/publication/ac549839?page=5"> Hepatology Prof Jean-Francois Dufour, Clinic </a> <a title="EMJ Hepatology 4.1 2016 page 6" href="http://viewer.zmags.com/publication/ac549839?page=6"> SUBSCRIBE TOTHEEMJ NEWSLETTER NwEwwW.newSs.eLmjEr</a> <a title="EMJ Hepatology 4.1 2016 page 7" href="http://viewer.zmags.com/publication/ac549839?page=7"> Welcome Welcome to the latest edition of EMJ H</a> <a title="EMJ Hepatology 4.1 2016 page 8" href="http://viewer.zmags.com/publication/ac549839?page=8"> gehealthcare.com GE Healthcare Ultrasound. Co</a> <a title="EMJ Hepatology 4.1 2016 page 9" href="http://viewer.zmags.com/publication/ac549839?page=9"> Foreword </a> <a title="EMJ Hepatology 4.1 2016 page 10" href="http://viewer.zmags.com/publication/ac549839?page=10"> 10 HEPATOLOGY • May 2016 </a> <a title="EMJ Hepatology 4.1 2016 page 11" href="http://viewer.zmags.com/publication/ac549839?page=11"> HEPATOLOGY • May 2016 </a> <a title="EMJ Hepatology 4.1 2016 page 12" href="http://viewer.zmags.com/publication/ac549839?page=12"> HEPATOLOGY • May 2016 </a> <a title="EMJ Hepatology 4.1 2016 page 13" href="http://viewer.zmags.com/publication/ac549839?page=13"> Congress Highlights New Research Hig</a> <a title="EMJ Hepatology 4.1 2016 page 14" href="http://viewer.zmags.com/publication/ac549839?page=14"> that it may be possible to vaccinate a single ind</a> <a title="EMJ Hepatology 4.1 2016 page 15" href="http://viewer.zmags.com/publication/ac549839?page=15"> In the study, the medical records of 128 c</a> <a title="EMJ Hepatology 4.1 2016 page 16" href="http://viewer.zmags.com/publication/ac549839?page=16"> detectable HCV. Fatigue was a side effect in 30% </a> <a title="EMJ Hepatology 4.1 2016 page 17" href="http://viewer.zmags.com/publication/ac549839?page=17"> HCV treatment across the board, and could provide</a> <a title="EMJ Hepatology 4.1 2016 page 18" href="http://viewer.zmags.com/publication/ac549839?page=18"> 5 days of presentations, discussions, and debates</a> <a title="EMJ Hepatology 4.1 2016 page 19" href="http://viewer.zmags.com/publication/ac549839?page=19"> A recent study, presented at ILC 2016</a> <a title="EMJ Hepatology 4.1 2016 page 20" href="http://viewer.zmags.com/publication/ac549839?page=20"> in 7.6% of all patients (n=26) with </a> <a title="EMJ Hepatology 4.1 2016 page 21" href="http://viewer.zmags.com/publication/ac549839?page=21"> Scoring System Defines Non-Alcoholic Fatty Liver D</a> <a title="EMJ Hepatology 4.1 2016 page 22" href="http://viewer.zmags.com/publication/ac549839?page=22"> alcohol-related than hepatitis C virus-induced sc</a> <a title="EMJ Hepatology 4.1 2016 page 23" href="http://viewer.zmags.com/publication/ac549839?page=23"> virological response 12 weeks after treatment (SV</a> <a title="EMJ Hepatology 4.1 2016 page 24" href="http://viewer.zmags.com/publication/ac549839?page=24"> Immunotherapy Offers Effective Treatment for Hepa</a> <a title="EMJ Hepatology 4.1 2016 page 25" href="http://viewer.zmags.com/publication/ac549839?page=25"> significantly associated with an increased risk of</a> <a title="EMJ Hepatology 4.1 2016 page 26" href="http://viewer.zmags.com/publication/ac549839?page=26"> US veterans’ health administration study </a> <a title="EMJ Hepatology 4.1 2016 page 27" href="http://viewer.zmags.com/publication/ac549839?page=27"> Vital Therapies® Seeks Subjects for ELAD® Clinica</a> <a title="EMJ Hepatology 4.1 2016 page 28" href="http://viewer.zmags.com/publication/ac549839?page=28"> Editorial Board Interviews Kenneth Simpson Senio</a> <a title="EMJ Hepatology 4.1 2016 page 29" href="http://viewer.zmags.com/publication/ac549839?page=29"> (NAFLD) did not exist, so both medical advances a</a> <a title="EMJ Hepatology 4.1 2016 page 30" href="http://viewer.zmags.com/publication/ac549839?page=30"> Q: How much of an issue is the lack of donors for</a> <a title="EMJ Hepatology 4.1 2016 page 31" href="http://viewer.zmags.com/publication/ac549839?page=31"> countries. We lag behind in some areas such as ac</a> <a title="EMJ Hepatology 4.1 2016 page 32" href="http://viewer.zmags.com/publication/ac549839?page=32"> WELCOME TO THE REAL WORLD: HEPATITIS C VIRUS </a> <a title="EMJ Hepatology 4.1 2016 page 33" href="http://viewer.zmags.com/publication/ac549839?page=33"> Real-World Experience: What Have We Learn</a> <a title="EMJ Hepatology 4.1 2016 page 34" href="http://viewer.zmags.com/publication/ac549839?page=34"> GT1. For GT4, however, there were limited Phase I</a> <a title="EMJ Hepatology 4.1 2016 page 35" href="http://viewer.zmags.com/publication/ac549839?page=35"> As mentioned, high SVR rates are achieved for cir</a> <a title="EMJ Hepatology 4.1 2016 page 36" href="http://viewer.zmags.com/publication/ac549839?page=36"> Table 2: Pharmacokinetics of direct-acting antivi</a> <a title="EMJ Hepatology 4.1 2016 page 37" href="http://viewer.zmags.com/publication/ac549839?page=37"> prioritised to avoid organ damage outside the liv</a> <a title="EMJ Hepatology 4.1 2016 page 38" href="http://viewer.zmags.com/publication/ac549839?page=38"> All the real-world studies and registries combine</a> <a title="EMJ Hepatology 4.1 2016 page 39" href="http://viewer.zmags.com/publication/ac549839?page=39"> elbasvir and grazoprevir with or without ribaviri</a> <a title="EMJ Hepatology 4.1 2016 page 40" href="http://viewer.zmags.com/publication/ac549839?page=40"> 2016. [Epub ahead of print]. 52. Roth D et al. Gr</a> <a title="EMJ Hepatology 4.1 2016 page 41" href="http://viewer.zmags.com/publication/ac549839?page=41"> If you are interested in submitting a paper to </a> <a title="EMJ Hepatology 4.1 2016 page 42" href="http://viewer.zmags.com/publication/ac549839?page=42"> Abstract Reviews EFFICACY AND SAFETY OF ELBASVIR/</a> <a title="EMJ Hepatology 4.1 2016 page 43" href="http://viewer.zmags.com/publication/ac549839?page=43"> ILC 2016 The majority of patients are genotype 1</a> <a title="EMJ Hepatology 4.1 2016 page 44" href="http://viewer.zmags.com/publication/ac549839?page=44"> Abstract Reviews in the SOF/PEG/RIBA group exper</a> <a title="EMJ Hepatology 4.1 2016 page 45" href="http://viewer.zmags.com/publication/ac549839?page=45"> ILC 2016 Methods Data on demographics, clinica</a> <a title="EMJ Hepatology 4.1 2016 page 46" href="http://viewer.zmags.com/publication/ac549839?page=46"> Abstract Reviews as lipopolysaccharides (LPS),</a> <a title="EMJ Hepatology 4.1 2016 page 47" href="http://viewer.zmags.com/publication/ac549839?page=47"> ILC 2016 gut-derived LPS, but also requires </a> <a title="EMJ Hepatology 4.1 2016 page 48" href="http://viewer.zmags.com/publication/ac549839?page=48"> Abstract Reviews group demonstrated in a randomi</a> <a title="EMJ Hepatology 4.1 2016 page 49" href="http://viewer.zmags.com/publication/ac549839?page=49"> ILC 2016 level, particularly for manufacturer</a> <a title="EMJ Hepatology 4.1 2016 page 50" href="http://viewer.zmags.com/publication/ac549839?page=50"> Abstract Reviews fibroblast growth factor 4 for 5</a> <a title="EMJ Hepatology 4.1 2016 page 51" href="http://viewer.zmags.com/publication/ac549839?page=51"> ILC 2016 After adjustment for competing mort</a> <a title="EMJ Hepatology 4.1 2016 page 52" href="http://viewer.zmags.com/publication/ac549839?page=52"> Abstract Reviews mice, the adverse effects o</a> <a title="EMJ Hepatology 4.1 2016 page 53" href="http://viewer.zmags.com/publication/ac549839?page=53"> ILC 2016 secrete a number of hormones, peptides,</a> <a title="EMJ Hepatology 4.1 2016 page 54" href="http://viewer.zmags.com/publication/ac549839?page=54"> Abstract Reviews we retrieved data from the </a> <a title="EMJ Hepatology 4.1 2016 page 55" href="http://viewer.zmags.com/publication/ac549839?page=55"> ILC 2016 In this Phase III study, patients with </a> <a title="EMJ Hepatology 4.1 2016 page 56" href="http://viewer.zmags.com/publication/ac549839?page=56"> Abstract Reviews disease develops in 5%, and in </a> <a title="EMJ Hepatology 4.1 2016 page 57" href="http://viewer.zmags.com/publication/ac549839?page=57"> Exclusive Videos from the International </a> <a title="EMJ Hepatology 4.1 2016 page 58" href="http://viewer.zmags.com/publication/ac549839?page=58"> EDITOR’S PICK In t</a> <a title="EMJ Hepatology 4.1 2016 page 59" href="http://viewer.zmags.com/publication/ac549839?page=59"> HEPATOCELLULAR CARCINOMA: AN OVERVIEW OF THE NUMB</a> <a title="EMJ Hepatology 4.1 2016 page 60" href="http://viewer.zmags.com/publication/ac549839?page=60"> present as a hypervascular lesion with washout in</a> <a title="EMJ Hepatology 4.1 2016 page 61" href="http://viewer.zmags.com/publication/ac549839?page=61"> side effects.26,27 Finally, patients with St</a> <a title="EMJ Hepatology 4.1 2016 page 62" href="http://viewer.zmags.com/publication/ac549839?page=62"> five genes including HN1, RAN, RAMP3, KRT19,</a> <a title="EMJ Hepatology 4.1 2016 page 63" href="http://viewer.zmags.com/publication/ac549839?page=63"> highly upregulated in HCC and was able to predict</a> <a title="EMJ Hepatology 4.1 2016 page 64" href="http://viewer.zmags.com/publication/ac549839?page=64"> Future Oncol. 2013;9(4):485-91. 28. Kondo F. H</a> <a title="EMJ Hepatology 4.1 2016 page 65" href="http://viewer.zmags.com/publication/ac549839?page=65"> THE INTERNATIONAL LIVER CONGRESS (ILC) 2016:</a> <a title="EMJ Hepatology 4.1 2016 page 66" href="http://viewer.zmags.com/publication/ac549839?page=66"> and safety.6,7 New data on RFX use in HE was pres</a> <a title="EMJ Hepatology 4.1 2016 page 67" href="http://viewer.zmags.com/publication/ac549839?page=67"> reductions in the number of hospital admissions a</a> <a title="EMJ Hepatology 4.1 2016 page 68" href="http://viewer.zmags.com/publication/ac549839?page=68"> changing intestinal permeability and inflammatory </a> <a title="EMJ Hepatology 4.1 2016 page 69" href="http://viewer.zmags.com/publication/ac549839?page=69"> NONSURGICAL TREATMENT FOR LOCALISED </a> <a title="EMJ Hepatology 4.1 2016 page 70" href="http://viewer.zmags.com/publication/ac549839?page=70"> particles given in conjunction with mul</a> <a title="EMJ Hepatology 4.1 2016 page 71" href="http://viewer.zmags.com/publication/ac549839?page=71"> and 6.4 months for DEB-TACE and cTACE</a> <a title="EMJ Hepatology 4.1 2016 page 72" href="http://viewer.zmags.com/publication/ac549839?page=72"> decompensation including ascites (0–18%) </a> <a title="EMJ Hepatology 4.1 2016 page 73" href="http://viewer.zmags.com/publication/ac549839?page=73"> study, the remaining three studies used at least </a> <a title="EMJ Hepatology 4.1 2016 page 74" href="http://viewer.zmags.com/publication/ac549839?page=74"> 9. Forner A et al. Hepatocellular carci</a> <a title="EMJ Hepatology 4.1 2016 page 75" href="http://viewer.zmags.com/publication/ac549839?page=75"> after transarterial chemoembolisation in Japa</a> <a title="EMJ Hepatology 4.1 2016 page 76" href="http://viewer.zmags.com/publication/ac549839?page=76"> FATTY LIVER DISEAS</a> <a title="EMJ Hepatology 4.1 2016 page 77" href="http://viewer.zmags.com/publication/ac549839?page=77"> FATTY ACIDS Fatty acids (FA) are carboxylic </a> <a title="EMJ Hepatology 4.1 2016 page 78" href="http://viewer.zmags.com/publication/ac549839?page=78"> sphingomyelinases and from the internalisatio</a> <a title="EMJ Hepatology 4.1 2016 page 79" href="http://viewer.zmags.com/publication/ac549839?page=79"> previous export from the mitochondria to th</a> <a title="EMJ Hepatology 4.1 2016 page 80" href="http://viewer.zmags.com/publication/ac549839?page=80"> Cholesterol catabolism into bile acids begins wit</a> <a title="EMJ Hepatology 4.1 2016 page 81" href="http://viewer.zmags.com/publication/ac549839?page=81"> in vivo.41 Cholesterol levels can therefore </a> <a title="EMJ Hepatology 4.1 2016 page 82" href="http://viewer.zmags.com/publication/ac549839?page=82"> 7. Alkhouri N et al. Lipotoxicity in nonalc</a> <a title="EMJ Hepatology 4.1 2016 page 83" href="http://viewer.zmags.com/publication/ac549839?page=83"> induced cytotoxicity in macrophages. Nat Cell Bio</a> <a title="EMJ Hepatology 4.1 2016 page 84" href="http://viewer.zmags.com/publication/ac549839?page=84"> IMMUNOPATHOGENESIS OF HEPATITIS B VIRUS INFECT</a> <a title="EMJ Hepatology 4.1 2016 page 85" href="http://viewer.zmags.com/publication/ac549839?page=85"> Hepatocarcinogenesis Healthy liver </a> <a title="EMJ Hepatology 4.1 2016 page 86" href="http://viewer.zmags.com/publication/ac549839?page=86"> or recycled back to the nucleus, thus promoting H</a> <a title="EMJ Hepatology 4.1 2016 page 87" href="http://viewer.zmags.com/publication/ac549839?page=87"> resulted in tumour regression following inhibitio</a> <a title="EMJ Hepatology 4.1 2016 page 88" href="http://viewer.zmags.com/publication/ac549839?page=88"> and rituximab; ofatumumab and rituximab must be s</a> <a title="EMJ Hepatology 4.1 2016 page 89" href="http://viewer.zmags.com/publication/ac549839?page=89"> Prevalence </a> <a title="EMJ Hepatology 4.1 2016 page 90" href="http://viewer.zmags.com/publication/ac549839?page=90"> Although hypermethylation has been labelled as th</a> <a title="EMJ Hepatology 4.1 2016 page 91" href="http://viewer.zmags.com/publication/ac549839?page=91"> 7. Karayiannis P et al. Hepatitis B virus DNA in </a> <a title="EMJ Hepatology 4.1 2016 page 92" href="http://viewer.zmags.com/publication/ac549839?page=92"> PloS One. 2011;6(5):e19862. 52. Kgatle M. A</a> <a title="EMJ Hepatology 4.1 2016 page 93" href="http://viewer.zmags.com/publication/ac549839?page=93"> EUROPEAN MEDICAL JOURNAL provides influential arti</a> <a title="EMJ Hepatology 4.1 2016 page 94" href="http://viewer.zmags.com/publication/ac549839?page=94"> MANIFESTATION OF NON-ALCOHOLIC FATTY LIVER DISE</a> <a title="EMJ Hepatology 4.1 2016 page 95" href="http://viewer.zmags.com/publication/ac549839?page=95"> occurring during human NAFLD/NASH. Depending on t</a> <a title="EMJ Hepatology 4.1 2016 page 96" href="http://viewer.zmags.com/publication/ac549839?page=96"> and thus may promote progression from NAFLD to NA</a> <a title="EMJ Hepatology 4.1 2016 page 97" href="http://viewer.zmags.com/publication/ac549839?page=97"> Most often, increased carbohydrate uptake is</a> <a title="EMJ Hepatology 4.1 2016 page 98" href="http://viewer.zmags.com/publication/ac549839?page=98"> exhibited a more severe phenotype of obesit</a> <a title="EMJ Hepatology 4.1 2016 page 99" href="http://viewer.zmags.com/publication/ac549839?page=99"> Table 2: Susceptibility of different common </a> <a title="EMJ Hepatology 4.1 2016 page 100" href="http://viewer.zmags.com/publication/ac549839?page=100"> Acknowledgements We thank Andreas Mariasevic for </a> <a title="EMJ Hepatology 4.1 2016 page 101" href="http://viewer.zmags.com/publication/ac549839?page=101"> mice. Hepatol. 2004;39(5):1286-96. 41. Larter </a> <a title="EMJ Hepatology 4.1 2016 page 102" href="http://viewer.zmags.com/publication/ac549839?page=102"> Genet. 2006;2(5):e81. 84. Farrell GC et al. Strai</a> <a title="EMJ Hepatology 4.1 2016 page 103" href="http://viewer.zmags.com/publication/ac549839?page=103"> NON-MALIGNANT PORTAL VEIN THROMBOSIS IN LIVER CIR</a> <a title="EMJ Hepatology 4.1 2016 page 104" href="http://viewer.zmags.com/publication/ac549839?page=104"> the prevalence of PVT evaluated by ultrasou</a> <a title="EMJ Hepatology 4.1 2016 page 105" href="http://viewer.zmags.com/publication/ac549839?page=105"> and the clinical situation of the patient at the </a> <a title="EMJ Hepatology 4.1 2016 page 106" href="http://viewer.zmags.com/publication/ac549839?page=106"> Secondary Prevention It is likely that antico</a> <a title="EMJ Hepatology 4.1 2016 page 107" href="http://viewer.zmags.com/publication/ac549839?page=107"> PVT in liver cirrhosis Recent (thrombus not dete</a> <a title="EMJ Hepatology 4.1 2016 page 108" href="http://viewer.zmags.com/publication/ac549839?page=108"> Treatment with TIPS may be feasible if por</a> <a title="EMJ Hepatology 4.1 2016 page 109" href="http://viewer.zmags.com/publication/ac549839?page=109"> 4. Gaiani S et al. Prevalence of spontaneous hepa</a> <a title="EMJ Hepatology 4.1 2016 page 110" href="http://viewer.zmags.com/publication/ac549839?page=110"> patients with portal thrombosis. Eur </a> <a title="EMJ Hepatology 4.1 2016 page 111" href="http://viewer.zmags.com/publication/ac549839?page=111"> Buyer’s Guide • ABBVIE • ADVANCED BIO. LAB (</a> <a title="EMJ Hepatology 4.1 2016 page 112" href="http://viewer.zmags.com/publication/ac549839?page=112"> SUBSCRIBE TO RECEIVE THE LATEST PUBLICATIONS, NE</a>